
Sign up to save your podcasts
Or


C16 Biosciences wants to replace palm oil, a major contributor to deforestation and climate change, with a lab-grown substitute. But CEO Shara Ticku faces a tough decision in bringing the product to market. Should she start small, with the lower volume personal care market? Or should she dive right into the booming lab-grown food market, with an interested investor? Harvard Business School Senior Lecturer Jeff Bussgang discusses his case, “C16 Biosciences: Lab-Grown Palm Oil.”
By HBR Presents / Brian Kenny4.5
190190 ratings
C16 Biosciences wants to replace palm oil, a major contributor to deforestation and climate change, with a lab-grown substitute. But CEO Shara Ticku faces a tough decision in bringing the product to market. Should she start small, with the lower volume personal care market? Or should she dive right into the booming lab-grown food market, with an interested investor? Harvard Business School Senior Lecturer Jeff Bussgang discusses his case, “C16 Biosciences: Lab-Grown Palm Oil.”

377 Listeners

1,449 Listeners

106 Listeners

170 Listeners

1,107 Listeners

3,993 Listeners

1,377 Listeners

747 Listeners

106 Listeners

173 Listeners

39 Listeners

796 Listeners

668 Listeners

219 Listeners

79 Listeners

163 Listeners

82 Listeners